Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA "Critical Path" Faces Roadblock

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency plans to release its list of top priorities several months behind schedule while it focuses on drug safety issues, Acting Deputy Commissioner Woodcock says. Limited FDA resources may jeopardize the project as well.
Advertisement

Related Content

"Critical Path" Priorities List Likely To Include Clinical Trial Design, FDAer Says
"Critical Path" Priorities List Likely To Include Clinical Trial Design, FDAer Says
Senate Drug Safety Hearings Will Take Broad View Of FDA Process
Senate Drug Safety Hearings Will Take Broad View Of FDA Process
Drug Safety Concerns May Slow Pharmaceutical Pipeline Further, FDA Says
Drug Safety Concerns May Slow Pharmaceutical Pipeline Further, FDA Says
Manhattan Institute Preparing FDA "Critical Path" Recommendations
Manhattan Institute Preparing FDA "Critical Path" Recommendations
Enriched Trials May Allow Sponsors To Seek Broad Labels, FDA's Temple Says
Enriched Trials May Allow Sponsors To Seek Broad Labels, FDA's Temple Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS058515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel